Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 178 entries
View as:

A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03261947 Org: User:
Start: 10/25/17 End: 08/24/20 Due: 08/24/21

Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01862328 Org: User:
Start: 06/10/13 End: 05/21/18 Due: 05/21/19

Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01335685 Org: User:
Start: 06/27/11 End: 12/29/16 Due: 12/29/17

A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia

Phase: N/A Priority: Normal
NCT ID: NCT04091438 Org: User:
Start: 01/26/20 End: 11/23/20 Due: 11/23/21

A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00652158 Org: User:
Start: 04/30/06 End: 04/30/08 Due: 04/30/09

A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)

Phase: N/A Priority: Normal
NCT ID: NCT03449030 Org: User:
Start: 04/23/18 End: 02/27/20 Due: 02/27/21

A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy Kidneys

Phase: N/A Priority: Normal
NCT ID: NCT04056455 Org: User:
Start: 03/04/20 End: 04/20/22 Due: 04/20/23

A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis

Phase: N/A Priority: Normal
NCT ID: NCT03544229 Org: User:
Start: 10/14/18 End: 07/15/21 Due: 07/15/22

A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of Carbon-14 ([14C])-Mobocertinib in Male Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT03811834 Org: User:
Start: 01/22/19 End: 03/11/19 Due: 03/11/20

A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00651664 Org: User:
Start: 10/22/07 End: 04/05/11 Due: 04/05/12

A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)

Phase: N/A Priority: Normal
NCT ID: NCT03268941 Org: User:
Start: 09/26/17 End: 03/09/18 Due: 03/09/19

Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment

Phase: N/A Priority: Normal
NCT ID: NCT01830816 Org: User:
Start: 09/16/13 End: 11/18/16 Due: 11/18/17

Study of MLN8237 in Participants With Advanced Hematological Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00697346 Org: User:
Start: 07/11/08 End: 10/19/16 Due: 10/19/17

A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03057366 Org: User:
Start: 05/11/17 End: 11/05/18 Due: 11/05/19

Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib

Phase: N/A Priority: Normal
NCT ID: NCT01714947 Org: User:
Start: 01/24/13 End: 06/14/13 Due: 06/14/14

Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01549951 Org: User:
Start: 05/31/12 End: 01/31/15 Due: 01/31/16

Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone

Phase: N/A Priority: Normal
NCT ID: NCT00507416 Org: User:
Start: 06/30/07 End: 03/31/13 Due: 03/31/14

Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01383928 Org: User:
Start: 10/31/11 End: 11/27/17 Due: 11/27/18

Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02135445 Org: User:
Start: 06/30/14 End: 12/31/15 Due: 12/31/16

Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448

Phase: N/A Priority: Normal
NCT ID: NCT01132404 Org: User:
Start: 11/30/10 End: 12/31/11 Due: 12/31/12

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Oral Dose of TAK-418 in Healthy Female Participants

Phase: N/A Priority: Normal
NCT ID: NCT03501069 Org: User:
Start: 05/30/18 End: 12/26/18 Due: 12/26/19

Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib

Phase: N/A Priority: Normal
NCT ID: NCT01844583 Org: User:
Start: 06/25/13 End: 09/06/16 Due: 09/06/17

PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00048230 Org: User:
Start: 06/30/02 End: 12/31/04 Due: 12/31/05

A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00500903 Org: User:
Start: 05/15/07 End: 02/23/11 Due: 02/23/12

Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function

Phase: N/A Priority: Normal
NCT ID: NCT02214147 Org: User:
Start: 08/21/14 End: 07/18/16 Due: 07/18/17